Press Release Details
Twist Bioscience Announces Technology Early Access of Enhanced Whole Genome Sequencing Solution at AGBT
Additional sequencing applications and reference standards to be highlighted at the conference
“In agricultural genomics, researchers constantly have to make a tradeoff between cost and insight. Deep sequencing across entire genomes is cost prohibitive, forcing researchers to turn to less costly approaches like genotyping by sequencing, microarrays, or low-pass WGS. These methods impose limits on the resolution, accuracy, or flexibility of experiments,” said Emily M. Leproust, Ph.D., CEO and co-founder of
The eWGS workflow starts with a modified Twist 96-plex library preparation kit that prepares 96 samples for sequencing in a single tube. This is followed by single-tube 96-plex enrichment on an aliquot of the library, using a customized panel to further enrich targets requiring more coverage. The original and enriched libraries are then combined into a single sequencer-ready pool that has both low whole genome coverage between 0.5x and 4x as well as high target-specific coverage. Researchers can tune the differential in coverage between low-pass and high-pass sites to fit their needs. Preparing and enriching 96 samples at a time for sequencing in a single pool can enable a high-throughput workflow and may reduce costs by using less materials and resources.
In addition to the technology early access of eWGS, Twist will have three posters highlighting applications of Twist’s next-generation sequencing (NGS) tools and reference standards available for viewing at the conference.
Details of the posters are as follows:
Poster: Use of synthetic CNV fragments to mimic copy number alterations for ctDNA reference standards
Poster: An RNA exome panel used to enrich transcript variants using cDNA libraries
Poster: Methylation Controls to detect for methylation level quantification in the Twist Targeted Methylation Sequencing workflow
Follow us on
Twist Bioscience Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated capabilities of the eWGS solution to enable researchers to obtain simultaneous low-pass whole genome data together with deep coverage of selected regions. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties relating to COVID-19; the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005576/en/
SVP, Corporate Affairs